Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Pancreatic Cancer Metastatic 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 19Cisplatin 11Capecitabine 9Oxaliplatin 7Fluorouracil 5pembrolizumab 4Leucovorin 4Sorafenib 3Magnetic Resonance Spectroscopy 3Erlotinib Hydrochloride 3trifluridine tipiracil drug combination 2regorafenib 2cobimetinib 2atezolizumab 2Trastuzumab 2Taxes 2Specimen Handling 2Platinum 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 21,2-diaminocyclohexaneplatinum II citrate 2zanidatamab 1varlilumab 1vandetanib 1tucatinib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gallbladder Neoplasms × devimistat × Clear all
NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
75 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡